Oncology | GSK US
WEBGSK scientists are focused on maximizing survival through the discovery and development of novel oncology medicines that may have life-changing potential. Our goal is for people with cancer to not only live, but to live well, as a result of our medicines.
GSK Oncology Pipeline
WEBOur unique R&D approach of Science x Technology x Culture is helping to fight cancer on multiple groundbreaking fronts – focusing on maximizing survival through the discovery and development of novel oncology medicines that may have life-changing potential.
Oncology - GSK
WEBWe have multiple investigational medicines in our oncology pipeline that have the potential to make a meaningful difference for patients with cancer, and we continue to grow our pipeline through targeted business development.
Pipeline | Oncology | GSK US Medical Affairs
WEBAt GSK, our pipeline is focused on unlocking the science of the immune system, human genetics, and advanced technologies to develop vaccines and specialty medicines. Our products in development progress through three stages: phase I, phase II, and phase III/registrational.
Jemperli (dostarlimab-gxly) plus chemotherapy approved in the US ... - GSK
WEBJul 31, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR ...
GSK’s Jemperli (dostarlimab) plus chemotherapy approved as the …
WEBDec 11, 2023 · GSK in oncology. GSK is committed to maximising patient survival through transformational medicines, with a current focus on breakthroughs in immuno-oncology and tumour-cell targeting therapies, and development in haematologic malignancies, gynaecologic cancers and other solid tumours.
Oncology - GSK
WEBOncology. This area of the website is intended for Canadian HCPs specializing in Oncology. GSK does not support or endorse any use of its products that is not consistent with the approved prescribing information in the official product monograph.
Ojjaara (momelotinib) approved in the US as the first and only ... - GSK
WEBSep 15, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythaemia), in adults with …
FDA approves GSK’s BLENREP (belantamab mafodotin-blmf) for …
WEBBLENREP is GSK’s fifth major medicine approval in 2020 across areas of significant unmet medical need such as cancer, HIV and chronic kidney disease. This approval marks the second FDA approval for GSK’s oncology portfolio in four months.
Products | Oncology | GSK US Medical Affairs
WEB(niraparib) Capsule Prescribing Information. Tablet Prescribing Information. More Product Information. Find GSK US oncology product information: Prescribing Information, storage and handling, and more.
Skip to content